An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine + RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma

Trial Profile

An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine + RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Obinutuzumab (Primary) ; Bendamustine
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms GADOLIN
  • Sponsors Genentech
  • Most Recent Events

    • 13 May 2017 Planned End Date changed from 1 Dec 2019 to 20 Aug 2020.
    • 12 Mar 2017 Results published in the Targeted Oncology
    • 07 Feb 2017 According to a Roche media release, Health Canada has approved GAZYVA (obinutuzumab) in combination with bendamustine followed by GAZYVA monotherapy for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a RITUXAN (rituximab)-containing regimen based on data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top